We serve Chemical Name:2-(1-benzofuran-2-yl)-2-oxoacetic acid CAS:39685-86-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(1-benzofuran-2-yl)-2-oxoacetic acid
CAS.NO:39685-86-4
Synonyms:2-Benzofurylglyoxylic acid;Benzofuran-2-yl-glyoxylsaeure;benzofuran-2-yl-glyoxylic acid
Molecular Formula:C10H6O4
Molecular Weight:190.15200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:330.3ºC at 760 mmHg
Density:1.435g/cm3
Index of Refraction:1.644
PSA:67.51000
Exact Mass:190.02700
LogP:1.70010
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Benzofurylglyoxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzofuran-2-yl-glyoxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Benzofurylglyoxylic acid Use and application,Benzofuran-2-yl-glyoxylsaeure technical grade,usp/ep/jp grade.
Related News: CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. Urea, N-(3,4-dichlorophenyl)-N’-(2-phenylethyl)- manufacturers The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. (Z)-1-((3,4,5-trihydroxy-24,34,44,54-hexaoxidan-2,4-dienyl)oxy)-14,23,33,44,53,63-hexaoxin-4-ol hydrate suppliers The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. europium(2+),hexabromosilicon(2-) vendor & factory CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. ,For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30.
